A pivotal study evaluating long term safety and efficacy of Pegvisomant in Japanese patients with acromegaly.

Trial Profile

A pivotal study evaluating long term safety and efficacy of Pegvisomant in Japanese patients with acromegaly.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Mar 2017

At a glance

  • Drugs Pegvisomant (Primary)
  • Indications Acromegaly
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Mar 2017 New trial record
    • 25 Apr 2016 Results of integrated safety and efficacy analysis of A6291011 and A6291009 trials, published in the Endocrine Journal
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top